Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15536153 | 0.94 | USP2 (0.53) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15380459 | 0.89 | USP2 (0.47) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15379873 | 0.89 | USP2 (0.47) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15380035 | 0.88 | USP2 (0.49) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15379802 | 0.87 | NAMPT (0.47) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15379165 | 0.87 | PTPN2 (0.56) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15379162 | 0.87 | PTPN2 (0.56) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15378949 | 0.86 | USP2 (0.48) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15380134 | 0.86 | SMN1; SMN2 (0.44) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 | |
| SCHEMBL15379501 | 0.86 | USP2 (0.49) | USP2ALOX15SMN1; SMN2HSD17B10TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847181-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013170115-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | USP2 2018/4885ALOX15 4389/4885SMN1; SMN2 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.